HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Myocardial tissue elastic properties determined by atomic force microscopy after stromal cell-derived factor 1α angiogenic therapy for acute myocardial infarction in a murine model.

AbstractOBJECTIVES:
Ventricular remodeling after myocardial infarction begins with massive extracellular matrix deposition and resultant fibrosis. This loss of functional tissue and stiffening of myocardial elastic and contractile elements starts the vicious cycle of mechanical inefficiency, adverse remodeling, and eventual heart failure. We hypothesized that stromal cell-derived factor 1α (SDF-1α) therapy to microrevascularize ischemic myocardium would rescue salvageable peri-infarct tissue and subsequently improve myocardial elasticity.
METHODS:
Immediately after left anterior descending coronary artery ligation, mice were randomly assigned to receive peri-infarct injection of either saline solution or SDF-1α. After 6 weeks, animals were killed and samples were taken from the peri-infarct border zone and the infarct scar, as well as from the left ventricle of noninfarcted control mice. Determination of tissues' elastic moduli was carried out by mechanical testing in an atomic force microscope.
RESULTS:
SDF-1α-treated peri-infarct tissue most closely approximated the elasticity of normal ventricle and was significantly more elastic than saline-treated peri-infarct myocardium (109 ± 22.9 kPa vs 295 ± 42.3 kPa; P < .0001). Myocardial scar, the strength of which depends on matrix deposition from vasculature at the peri-infarct edge, was stiffer in SDF-1α-treated animals than in controls (804 ± 102.2 kPa vs 144 ± 27.5 kPa; P < .0001).
CONCLUSIONS:
Direct quantification of myocardial elastic properties demonstrates the ability of SDF-1α to re-engineer evolving myocardial infarct and peri-infarct tissues. By increasing elasticity of the ischemic and dysfunctional peri-infarct border zone and bolstering the weak, aneurysm-prone scar, SDF-1α therapy may confer a mechanical advantage to resist adverse remodeling after infarction.
AuthorsWilliam Hiesinger, Matthew J Brukman, Ryan C McCormick, J Raymond Fitzpatrick 3rd, John R Frederick, Elaine C Yang, Jeffrey R Muenzer, Nicole A Marotta, Mark F Berry, Pavan Atluri, Y Joseph Woo
JournalThe Journal of thoracic and cardiovascular surgery (J Thorac Cardiovasc Surg) Vol. 143 Issue 4 Pg. 962-6 (Apr 2012) ISSN: 1097-685X [Electronic] United States
PMID22264415 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Chemical References
  • Angiogenesis Inducing Agents
  • Chemokine CXCL12
Topics
  • Angiogenesis Inducing Agents (pharmacology)
  • Animals
  • Biomechanical Phenomena
  • Chemokine CXCL12 (pharmacology)
  • Disease Models, Animal
  • Elastic Modulus
  • Elasticity Imaging Techniques (methods)
  • Fibrosis
  • Heart Ventricles (drug effects, pathology, physiopathology)
  • Male
  • Mice
  • Microscopy, Atomic Force
  • Myocardial Infarction (drug therapy, pathology, physiopathology)
  • Myocardium (pathology)
  • Neovascularization, Physiologic (drug effects)
  • Time Factors
  • Ventricular Remodeling (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: